Saturday, July 5, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

European University to Fund Core One Labs’ Akome Advanced Neurogenesis Stimulation Studies

by Euro Times
October 15, 2022
in Markets
Reading Time: 4 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


VANCOUVER, BC / ACCESSWIRE / October 14, 2022 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN:A3CSSU) (the “Company” or “Core One“), further to its press release dated August 18, 2022, is excited to announce its wholly owned subsidiary, Akome Biotech Ltd. (“Akome“), the Company’s bio-pharma research and development division focused on new psychedelic-based drug discovery and development targeting neurological and mental health disorders, is finalizing discussions with Madrid’s Universidad Complutense (“Universidad Complutense”) to fund and initiate advancement of its neurogenesis stimulation studies (“neurogenesis studies“) relating to the effectiveness of its specific plant bioactives (“bioactive compounds) that comprise part of their patent pending psychedelic-based drug formulations. The Universidad Complutense has expressed a strong interest in advancing the next stage studies, and will providefunding to complete the studies, with Akome only required to provide raw materials.

As reported in the Company’s August 18, 2022, press release the neurogenesis studies, conducted by Universidad Complutense provide very encouraging results, having revealed that Akome’s selected bioactive compounds induce remarkable neurogenetic activity in controlled tests. Furthermore, the studies strongly suggest that each of Akome’s selected bioactive compounds have significant potential to elicit therapeutic activity against multiple neurologic conditions and could have therapeutic effects in more than just one targeted disease.

As a result of the encouraging studies results Akome, and Dr. Jose A. Morales-Garcia, Professor of Universidad Complutense and member of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) from Carlos III Health Institute, have initiated discussions and are currently mapping out advanced neurogenesis models. The objectives of the next stage of the program include to test all Akome’s bioactive compounds in combination with select psychedelic compounds; to define potential pharmacodynamics; as well as to assist in the design of the next set of studies to demonstrate beneficial effects in animal models of the neurologic diseases and mental health conditions.

“The results of the initial study were very promising, and the Universidad Complutense is eager to move forward with the next stages of this trial and has offered to provide the funding required to conduct the research,” Core One CEO, Joel Shaker commented. “Moving forward with this advanced neurogenesis study in partnership with Universidad Complutense marks another significant step forward in the Company’s drug development pipeline.”

“The commitment expressed by Universidad Complutense to move forward with advanced neurogenesis studies, is a welcomed vote of confidence at this stage of our drug development process and marks another significant step forward and their potential for success.”

About Core One Labs Inc.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:

[email protected]
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

SOURCE: Core One Labs Inc.

View source version on accesswire.com:
https://www.accesswire.com/720546/European-University-to-Fund-Core-One-Labs-Akome-Advanced-Neurogenesis-Stimulation-Studies



Source link

Tags: AdvancedAkomeCoreEuropeanfundLabsNeurogenesisStimulationStudiesUniversity
Previous Post

Biden campaigns with Katie Porter on work to lower drug costs

Next Post

What to expect from China’s party congress

Related Posts

In Dollar We Trust – Banyan Hill Publishing

In Dollar We Trust – Banyan Hill Publishing

by Ian King
July 5, 2025
0

The markets are closed at present, however I wished to take the time to want you a contented and affluent...

Big, Beautiful, and Baffling: What The Law May Mean for Your Finances

Big, Beautiful, and Baffling: What The Law May Mean for Your Finances

by Kendall Blythe
July 4, 2025
0

Evan El-Amin / Shutterstock.comCongress has handed one of the vital far-reaching items of laws in latest reminiscence: the “One Large...

Trump’s ‘big beautiful bill’ passes SALT deduction limit of ,000

Trump’s ‘big beautiful bill’ passes SALT deduction limit of $40,000

by Kate Dore, CFP®, EA
July 3, 2025
0

U.S. Home of Representatives Speaker Mike Johnson speaks after the U.S. President Donald Trump's sweeping spending and tax invoice passes,...

Coinbase shines on stablecoin boom, S&P 500 debut. Will the rally continue?

Coinbase shines on stablecoin boom, S&P 500 debut. Will the rally continue?

by Staff Correspondent
July 5, 2025
0

Coinbase World, Inc. (NASDAQ: COIN) has emerged as the most important and most user-friendly cryptocurrency trade within the US, since...

5 Budget-Friendly Organization Hacks That Cut Household Expenses by 0+ Per Year

5 Budget-Friendly Organization Hacks That Cut Household Expenses by $200+ Per Year

by Crystal Paine
July 4, 2025
0

Whereas getting organized generally seems like a luxurious we don’t have time for, it may be a superb money-saving hack,...

What the ‘Big, Beautiful Bill’ Means for Your Finances

What the ‘Big, Beautiful Bill’ Means for Your Finances

by Anna Helhoski
July 4, 2025
0

President Donald J. Trump's “huge, stunning invoice” has cleared the end line in Congress. Its provisions are anticipated to dramatically...

Next Post
What to expect from China’s party congress

What to expect from China's party congress

Rupert Murdoch considers combining Fox, News Corp By Reuters

Rupert Murdoch considers combining Fox, News Corp By Reuters

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Will UAE residency be affected if you apply for citizenship in other countries? GDRFA chief clarifies rules | World News

Will UAE residency be affected if you apply for citizenship in other countries? GDRFA chief clarifies rules | World News

July 5, 2025
BNB Gets Big Backer as Nano Labs Begins Billion-Dollar Accumulation

BNB Gets Big Backer as Nano Labs Begins Billion-Dollar Accumulation

July 5, 2025
Cathie Wood Suggests Government Settlement in Bitcoin Shift

Cathie Wood Suggests Government Settlement in Bitcoin Shift

July 5, 2025
Kenyan president plans to build huge church at his official residence

Kenyan president plans to build huge church at his official residence

July 5, 2025
Things Are About To Get Very Ugly For Republicans Who Voted To Cut Medicaid And SNAP

Things Are About To Get Very Ugly For Republicans Who Voted To Cut Medicaid And SNAP

July 5, 2025
MDLZ Quantitative Stock Analysis | Nasdaq

MDLZ Quantitative Stock Analysis | Nasdaq

July 5, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Will UAE residency be affected if you apply for citizenship in other countries? GDRFA chief clarifies rules | World News

BNB Gets Big Backer as Nano Labs Begins Billion-Dollar Accumulation

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In